Login
Xilio Therapeutics, Inc. logo

Xilio Therapeutics, Inc.

xiliotx.com

What Do They Do?

Develops cancer immunotherapies designed to activate inside tumors, including treatments that direct immune cells against cancer cells, for patients with cancer.

How Do They Make Money?

Xilio earns collaboration and license revenue from partners for rights to therapies and related development services. Contracts may provide upfront fees, development or regulatory milestones, and royalties on licensed-product sales; payments follow contract billing schedules, while revenue is tied to delivery of licenses or services.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical partners, including AbbVie and Gilead, work directly with Xilio through collaboration and license agreements for masked therapies and development work.

Do Revenues Turn Into Profits?

No. It lost $35M in FY2025.

Operating income, FY2025
−96% of revenue
▲ +31% (Loss) vs FY2024 (−$60.6M, −955%)
Net income, FY2025
−80% of revenue
▲ +40% (Loss) vs FY2024 (−$58.2M, −918%)
Free cash flow, FY2025
−13% of revenue
▲ +70% (Loss) vs FY2024 (−$18.4M, −290%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −48%
vs $19.1M in Q3 FY2025
Net income
▲ +63% (Loss)
vs −$16.3M in Q3 FY2025

Pipeline expansion The older report centered its named clinical candidates on tumor-activated cytokine and checkpoint-inhibitor therapies; the latest report also describes masked T-cell engager programs, including wholly owned candidates and a program with AbbVie.

Partnership model The older report described Xilio as holding development and commercialization rights to its candidates while seeking partnerships; the latest describes licensing and collaboration arrangements with outside companies.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support